E. Gifford Upjohn (1904–1993) was an American executive.
E. Gifford Upjohn was born in 1904 in Michigan.[1] He was a grandnephew of founder William E. Upjohn.[2] He earned his Ph.D. from the University of Michigan Medical School in 1928 and completed an internship at the University Hospital in Ann Arbor, Michigan.[2]
Upjohn started his career in 1930 by joining family business, The Upjohn Company.[2]
In 1937, Upjohn company's medical division, at a time when the relationship between pharmaceutical companies and the American Medical Association was marked by skepticism.[2] [3]
Upjohn progressed through various roles, becoming vice president and medical director in 1943, and then executive vice president in 1951.[4] [2] He was appointed president of the company in 1953, and in 1962, he became chairman, a position he held until his retirement in 1969.[4] [2] He remained a board member until 1978.[2]
In 1970, the University of Michigan named a new center for clinical pharmacology after him, when he donated a $1.1 million to the university.[2]
His contributions extended to regulatory matters in the pharmaceutical industry.[3] Upjohn testified at U.S. Senate hearings in 1959 and 1960, focusing on drug pricing.[3] These hearings contributed to legislation that required pharmaceutical companies to demonstrate the safety and effectiveness of their products before market introduction, a shift from earlier regulations that did not mandate such proof through clinical trials.[3] [1]